Skip to main content
. 2021 Apr 27;6(11):4209–4242. doi: 10.1016/j.bioactmat.2021.04.021

Fig. 8.

Fig. 8

(a) In vivo CT images of 4T1 tumor-bearing mice before and 6 h after intravenous injection with PEG-MoS2-Au-Ce6 nanocomposites, tumor (T) and liver (L). (b) In vivo CT images of tumors on mice before and 6 h after intravenous injection with PEG-MoS2-Au-Ce6 nanocomposites. (c) Corresponding HU value of PEG-MoS2-Au-Ce6 nanocomposites in the tumor before injection and 6 h after injection. Reprinted with permission from Ref. [175]. Copyright 2017, Journal of materials chemistry. (d) Scheme presenting the 64Cu labeling on MoS2-IO-(d)PEG via a chelator-free manner. (e) PET images of 4T1 tumor-bearing mice taken at various time points post iv injection of 64Cu-MoS2-IO-(d)PEG. The blue dot circles highlight the 4T1 tumor site of mice. (f) Quantification of 64Cu-MoS2-IO-(d)PEG uptake in the tumor and muscle, as well as the tumor/muscle (T/M) ratio at various time points pi. Reprinted with permission from Ref. [177]. Copyright 2015, ACS nano. (g) In vivo T1-weighted MR images of Balb/c mice after injection at different time points (pre-injection, 1 h, 2 h, 4 h, 8 h). Reprinted with permission from Ref. [178]. Copyright 2018, Journal of materials chemistry.